Drug reference

Galcanezumab

Monoclonal Antibody · Anti-migraine agent, Migraine prophylaxis

Monoclonal AntibodyAnti-migraine agent, Migraine prophylaxis

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Manufacturer advises avoid—limited information available.

FDA category + note

Mechanism

Galcanezumab is a monoclonal antibody that binds specifically to the calcitonin gene-related peptide (CGRP) ligand. By binding to CGRP, it prevents CGRP from binding to and activating its receptor. This mechanism inhibits CGRP function, thereby preventing migraine attacks.

Indications

Prophylaxis of migraine (in patients who have at least 4 migraine days per month and whose migraine is not adequately controlled by oral agents)Prophylaxis of cluster headache

Dosing

Adult: Subcutaneously once per month.

Side effects

Common

Hypersensitivity

Serious

Hypersensitivity

Pregnancy & lactation

Pregnancy

Manufacturer advises avoid—limited information available.

Lactation

Manufacturer advises avoid during first few days after birth—possible risk from transfer of antibodies to infant. After this time, use during breastfeeding only if clinically needed.